← Back to Pipeline Dashboard Open Source Medicine Foundation

ACC-001+ QS21 (3mcg)

Discontinued / Inactive

Developer: Pfizer  |  Target Disease: Alzheimer Disease

Program Status: Inactive / Discontinued

Reason: Registry status: TERMINATED

Stage at discontinuation: phase_2

Development Phase Discontinued / Inactive Primary Status
Platform Technology Biological (unspecified platform) Biologic Architecture
Target Indication Alzheimer Disease Pathogen / Antigen
Last Verified 2026-07-10 Tier 1 Multi-Source Checked

Multi-Jurisdiction Regulatory Status

Official licensing, rolling submissions, or authorization status tracked across major health authorities.

Regulatory Authority Status & Details
US FDA Not Filed / Pre-submission
EMA (Europe) Not Filed / Pre-submission
Health Canada Not Filed / Pre-submission
TGA (Australia) Not Filed / Pre-submission

Scientific Profile & Documentation

Platform Architecture
Biological (unspecified platform)
Lead Developer
Pfizer
Next Expected Milestone
Primary completion (most advanced trial): 2013-12 (registry estimate)
Analyst & Development Notes
Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.
Primary Source Documentation
ClinicalTrials.gov NCT00960531 →

Registered Clinical Trials & Studies

Direct registry links to active, completed, or pivotal registration studies across phases.

NCT00960531 Discontinued / Inactive

A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease

Status: Active / Ongoing • Expected Readout: 2013-12

Milestone Overview

  • Stage Verification
    Discontinued / Inactive confirmed as of 2026-07-10.
  • Target Milestone
    Primary completion (most advanced trial): 2013-12 (registry estimate)

Vaccine Data Navigator Candidate Profile Registry:

This candidate profile is indexed across all clinical development levels (Preclinical through Phase 1–3, Regulatory Filing, and Licensure) from primary registry databases (ClinicalTrials.gov, WHO ICTRP, FDA CBER, EMA, Health Canada, TGA Australia). Data are updated continuously to track global biologic and vaccine pipelines.